A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Clinical trial NCT05604560 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05604560
- Sponsor
- Lei Zheng
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-08
- Primary completion
- 2026-09-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.